54 results about "Tetrapyrrole" patented technology

The present invention pertains to a process for the carbonylation of an epoxide by reacting it with carbon monoxide in the presence of a catalyst system containing two components, wherein the first component is a source of one or more metals selected from the group consisting of cobalt, ruthenium and rhodium, and the second component is a coordination complex of a tetrapyrrole compound with one or more of the metals belonging to the group consisting of groups IIIA and IIIB of the periodic system, lanthanides and actinides. The present invention also pertains a process for the preparation of a catalyst system.

A photosensitive tetrapyrrole derivative having formula (I)where n stands for 1 or 2 or a pharmaceutically acceptable salt thereof is useful as an effective ingredient in an obstruent composition for photochemotherapeutically obstructing neovascular vessels. The photosensitive tetrapyrroles of the formula (I) may be administered in a photochemotherapeutic method for obstructing neovascular vessels, particularly choroidal and retinal neovascularizations.

The present invention relates to a process for the carbonylation of epoxides by reacting epoxides with carbon monoxide in the presence of a two-component catalyst system, wherein the first component is one or more of cobalt, ruthenium and rhodium. A variety of metal sources, the second component is a coordination complex of tetrapyrrole compound and one or more metals belonging to IIIA and IIIB groups, lanthanides and actinides in the periodic system. The invention also relates to a process for the preparation of the catalyst system and the use of the catalyst system in the carbonylation of epoxides.

A method of making a metalloporphyrin is carried out by reacting (i) a linear tetrapyrrole, said linear tetrapyrrole having a 19-acyl group and a 1-protecting group, with (ii) a metal salt under basic conditions to produce the metalloporphyrin. Products produced by such methods and intermediates useful for carrying out such methods are also described.

The invention relates to a genetically modified prokaryotic cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) and one or more transgenes or upregulated endogenous genes encoding iron-sulfur (Fe—S) cluster polypeptides or proteins that catalyze complex radical-mediated molecular rearrangements, electron transfer, radical or non-redox reactions, sulfur donation or perform regulatory functions. The prokaryotic cells are characterized by enhanced activity of these iron-sulfur (Fe—S) cluster polypeptides, enhancing their respective functional capacity, and facilitating enhanced yields of compounds in free and protein-bound forms, including heme, hemoproteins, tetrapyrroles, B vitamins, amino acids, δ-aminolevulinic acid, biofuels, isoprenoids, pyrroloquinoline quinone, ammonia, indigo, or their precursors, whose biosynthesis depends on their activity. The invention further relates to a method for producing said compounds or their precursors using the genetically modified prokaryotic cell of the invention, and the use of the genetically modified prokaryotic cell.

This invention features a method for eliciting an antioxidative effect. The method includes administering to a subject (e.g., an animal or human) in need thereof an effective amount of a tetrapyrrole compound of formula (I): Each of R, R, R<c>, R<d>, R<e>, R<f>, R<g>, and R<h>, independently, is H or alkyl; R1 is alkyl or CHO; R2 is alkyl; R3 and R4 taken together are part of a cyclyl or heterocyclyl ring, and R5 is (CH2)mCOOR, in which R is H, and m is 1, 2, or 3; or R3 is (CH2), COOR', C(O)(CH2)nCOOR', CH(OH)(CH2)nCOOR', and R4 and R5 taken together are part of a cyclyl or heterocyclyl ring, in which R' is H or alkyl, and n is 0, 1, 2, or 3; and R6 is alkenyl or CHO; the tetrapyrrole compound optionally being chelated with Mg<2+>, Mn<2+>, Cu<2+>, Fe<2+>, Co<2+>, Ni<2+>, or Zn<2+> through the nitrogen atoms on the four pyrrole rings.

A method for treating helminthic infections in a mammal or plant which entails administering one or more compounds which are metal-ligand chelate compounds containing a metal and a tetrapyrrole compound or a porphyrin compound, to mammal or plant in need thereof.

The invention relates to a novel intermediate di(disubstituted) phenyl dihalogenated porphin derivative which is stable in performance, good in hydrophilicity and not prone to aggregation and an application thereof. The compound has the following structures (I) and (II), wherein X is Cl, Br or I; A and Y are the same or different and are independently CH2 or O; R1 and R2 are different, R3 and R4 are the same or different, at least one of R3 and R4 contains a polar group, and R3 and R4 are independently alkyl groups, alkyl groups containing N or O atoms, alkyl groups containing carbonyl groups or alkyl groups containing amido bonds or alkyl carboxylic acid, alkyl alcohol, alkyl carboxylic acid containing N or O atoms, alkyl alcohol containing N or O atoms, alkyl carboxylic acid containing carbonyl groups, alkyl alcohol containing carbonyl groups, alkyl carboxylic acid containing amido bonds, and alkyl carboxylic acid containing carbonyl groups and amido bonds at the same time. The prepared intermediate dihalogenated diphenyl porphin photosensitizer has remarkable photodynamic activity, and can be used as a drug for photodynamic diagnosis and treatment of diseases such as tumors, retina macular degeneration, actinic keratosis, nevus flammeus and condyloma acuminata.

A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof.

In order to overcome the defects of poor stability, short shelf life and the like of a hypochlorous acid disinfectant in the prior art, the invention provides a stable hypochlorous acid disinfectant which comprises a mixture of the following components: a hypochlorite aqueous solution, a pH regulator, a stabilizer and a diluent, wherein the stabilizer is water-soluble porphyrin, porphyrin has a tetrapyrrole conjugated large pi rigid plane and a plurality of conjugated delocalized pi electrons, and can form ppi conjugation with Cl in hypochlorous acid, so that the hypochlorous acid structure ismore stable, the stability of the hypochlorous acid disinfectant is improved, the shelf life of the hypochlorous acid disinfectant is prolonged, the pH regulator is an acidic regulator, and the diluent is a buffer solution of conjugated acid-base pairs. The invention also provides a preparation method of the hypochlorous acid disinfectant and application of the hypochlorous acid disinfectant in the aspects of instrument disinfection, object surface disinfection, skin disinfection and air disinfection.

The invention discloses application of a BUIPTP (binuclear uranyl-isophthalaldehyde-tetrapyrrole) to ATP (Adenosine Triphosphate) analysis and belongs to the technical field of biochemical analysis detection method. The application comprises the following steps: determining optimal conditions for detecting ATP; preparing a BUIPTP detection base solution; drawing a standard curve of determined ATP;analyzing the content of the ATP in a sample: weighing a sample to be detected, which contains the ATP; adding water for dissolving or diluting; adding a Tris-HCl buffering solution; while stirring,dropwise adding the BUIPTP detection base solution into the solution; determining second-grade scattering spectral intensity at a part with optimal wavelength. By adopting a detection method providedby the invention, the deviation between the detected ATP concentration and objective concentration is less than 2.5 percent; the detection method provided by the invention has very high accuracy; whenthe concentration of the ATP is lower than 0.75nmol.L<-1>, the ATP still can be detected; the detection method has a good detection effect in a range of 2.5 to 500nmol.L<-1>.

It is intended to provide a functional molecular element having a specific conductivity, which is a functional molecular element having a structure enabling reduction in the contact resistance at the interface between a constituting molecule and an electrode, a process for producing the same and a functional moleucalr device. A n-electron conjugated molecule (1), which is one species of linear tetrapyrrole having an almost disc-shaped central skeleton (2) and a flexible side chain (3) consisting of an alkyl group, is dissolved in 4-pentyl-4'-cyanobiphenyl or tetrahydrofuran and the concentration is adjusted to an appropriate level. This solution is adhered to electrodes (5) and (6) and the solvent is evaporated. Thus, an array structure (4) of the n-electron conjugated molecule (1) is self-organizingly formed. An adsorbed molecule (9) in the first layer of the array structure (4) is fixed in such a manner that its side chain (3) is adsorbed on the surface of the electrode (5) or (6) while the almost disc-shaped face of the sekeleton (2) is adhered in parallel to the surface of the electrode (5) or (6). The stacking direction of the n-electron conjugated molecule (1) in the second layer and thereafter of the array structure (4) is regulated by the n-n interaction between the disc-shaped face of the sekeletons (2).

A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50 nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof.